The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations
The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations
复制标题
DOI：
10.1016/j.vaccine.2011.05.086
复制
发表时间：
2011-07-26
期刊：
影响因子：
5.5
通讯作者：
Hennessy, Thomas W.
中科院分区：
文献类型：
--
作者：
Said, Maria A.;O'Brien, Katherine L.;Hennessy, Thomas W.
阿拉斯加原住民和一些美洲印第安人（AI/AN）人群在儿童和成人人群中患侵袭性肺炎球菌疾病（IPD）的比例与美国总人口相比高得不成比例。目前在美国有两种肺炎球菌疫苗：一种是23价肺炎球菌多糖疫苗（PPSV23），自1983年起上市，推荐用于老年人和2岁以上有潜在疾病的人；另一种是13价肺炎球菌结合疫苗（PCV13），自2010年起用于婴儿常规免疫计划。美国免疫实践咨询委员会（ACIP）此前建议对生活在特殊环境或社会环境中的人使用PPSV23，包括2-64岁的AN和某些AI患者，因为他们的发病率较高。建议在AI/AN人群中常规使用PPSV23
Alaska Native and some American Indian (AI/AN) populations suffer disproportionately high rates of invasive pneumococcal disease (IPD) in both the pediatric and adult populations compared to the general U.S. population. Two pneumococcal vaccines are currently available in the U.S.: a 23-valent pneumococcal polysaccharide vaccine (PPSV23), available since 1983 and recommended for the elderly and those over 2 years of age with underlying medical conditions, and a 13-valent pneumococcal conjugate vaccine (PCV13), used in the routine infant immunization schedule since 2010. The U.S. Advisory Committee on Immunization Practice (ACIP) previously recommended use of PPSV23 for persons living in special environments or social settings, including AN and certain AI persons 2-64 years of age, on the basis of higher disease rates. The recommendation for routine PPSV23 use among AI/AN persons